Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Intra-Cellular Therapies (ITCI) Prices 6.9M Common Stock Offering at $43.50/Share
September 23, 2015 6:46 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) announced the pricing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to... More
Intra-Cellular Therapies (ITCI) to Offer $300M in Common Stock
September 21, 2015 4:12 PM EDTIntra-Cellular Therapies (NASDAQ: ITCI) announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15%... More
Intra-Cellular Therapies (ITCI) Commences $300M Common Stock Offering
September 21, 2015 4:12 PM EDTIntra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to... More
